Tylenol-Maker Kenvue Shares Bounce, Trump Claims Face Pushback

Reuters
09/23

Sept 23 (Reuters) - Tylenol-maker Kenvue KVUE.N stock rose in European trading on Tuesday, even after U.S. President Donald Trump linked its popular pain medication to autism risk during pregnancy.

Kenvue's shares gained 6% in premarket, rebounding from a record low hit the previous day ahead of Trump's extraordinary White House press conference.

Citi analysts said they expected the stock to recover, citing the absence of new scientific evidence.

"Overall, we see limited judicial risk following today's announcement, but there could be some impact on Tylenol consumption due to negative headlines," they wrote.

Many doctors reject the claim, and Kenvue reiterated there is no scientific link between acetaminophen, the active ingredient in Tylenol, and autism, warning that such suggestions could endanger maternal health.

The Food and Drug Administration said it will update labels on Tylenol and generic versions to reflect evidence of a possible link between acetaminophen use during pregnancy and neurological conditions such as autism and ADHD, but stressed that no causal relationship has been established.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10